A double-blind clinical study comparing the safety, tolerance and efficacy of ioversol and iohexol in intravenous urography.
A double-blind trial in 80 patients showed no significant difference in the efficacy, tolerance and safety for intravenous urography between the new contrast medium Ioversol (Optiray Mallinckrodt Inc.) and the well established medium Iohexol (Omnipaque, Nycomed [UK] Ltd). Minor transient rises in AST/ALT were noted in approximately 10% of each group which were regarded as clinically insignificant. Both media were well tolerated with no significant side-effects.
Colthurst
J R
JR
Department of Radiology, St Thomas' Hospital, London.
Chan
O
O
Creagh
M
M
Gordon
P
P
Guy
R
R
Muncey
F
F
Ayers
A B
AB
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003287:Contrast Media / Q000009:adverse effects; D004311:Double-Blind Method; D006801:Humans; D007472:Iohexol / Q000009:adverse effects; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000009:adverse effects; D014567:Urography / Q000379:methods*
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C054871:ioversol